The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study

被引：0

作者：

Francesco Russo

Michele Linsalata

Caterina Clemente

Benedetta D’Attoma

Antonella Orlando

Giovanna Campanella

Francesco Giotta

Giuseppe Riezzo

机构：

[1] National Institute for Digestive Diseases I.R.C.C.S. “Saverio de Bellis”,Laboratory of Experimental Biochemistry

[2] Medical Oncology Unit I.R.C.C.S. “Saverio de Bellis”,Laboratory of Experimental Pathophysiology

[3] Castellana Grotte,undefined

[4] Medical Oncology Unit I.R.C.C.S. “Giovanni Paolo II”,undefined

[5] National Institute for Digestive Diseases I.R.C.C.S. “Saverio de Bellis”,undefined

[6] Castellana Grotte,undefined

来源：

BMC Cancer | / 13卷

关键词：

Breast cancer; Chemotherapy-induced diarrhea; Epidermal growth factor; Intestinal permeability; Ghrelin; Glucagon-like peptide 2; Gut peptides; Zonulin;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Prospective randomized study of cyclophosphamide, epirubicin, and 5-fluorouracil versus cyclophosphamide, adriamycin, and 5-fluorouracil in advanced or recurrent breast cancer
Kobayashi T.
Koyama H.
Oka T.
Yasumura T.
Kan N.
Takatsuka Y.
Noguchi M.
Morimoto K.
Suzuki T.
Tobe T.
Mori T.
Breast Cancer, 1999, 6 (1) : 37 - 42
[32] Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients
M. Sandström
H. Lindman
P. Nygren
M. Johansson
J. Bergh
M.O. Karlsson
Cancer Chemotherapy and Pharmacology, 2006, 58
[33] Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients
Sandström, M
Lindman, H
Nygren, P
Johansson, M
Bergh, J
Karlsson, MO
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (02) : 143 - 156
[34] Ocular surface and tear film abnormalities in women under adjuvant chemotherapy for breast cancer with the 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) regimen
Karamitsos, A.
Kokkas, V
Goulas, A.
Paraskevopoulos, P.
Gougoulias, K.
Karampatakis, V
Boboridis, K.
HIPPOKRATIA, 2013, 17 (02) : 120 - 125
[35] Analysis of cardiac markers on patients receiving 5-fluorouracil, epirubicin, cyclophosphamide with concurrent celecoxib (FEC-C) neoadjuvant therapy for locally advanced breast cancer
Yip, Adrian Y. S.
Loo, Wings T.
Chow, Louis W. C.
CANCER RESEARCH, 2010, 70
[36] PHASE-III RANDOMIZED STUDY OF FLUOROURACIL, EPIRUBICIN, AND CYCLOPHOSPHAMIDE V FLUOROURACIL, DOXORUBICIN, AND CYCLOPHOSPHAMIDE IN ADVANCED BREAST-CANCER - AN ITALIAN MULTICENTER TRIAL
INTINI, C
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (06) : 976 - 982
[37] A PILOT-STUDY OF INTENSIVE CYCLOPHOSPHAMIDE, EPIRUBICIN AND FLUOROURACIL IN PATIENTS WITH AXILLARY NODE POSITIVE OR LOCALLY ADVANCED BREAST-CANCER
LEVINE, MN
BRAMWELL, V
PRITCHARD, K
PERRAULT, D
FINDLAY, B
ABUZAHRA, H
WARR, D
ARNOLD, A
SKILLINGS, J
EUROPEAN JOURNAL OF CANCER, 1993, 29A (01) : 37 - 43
[38] A PROSPECTIVE RANDOMIZED TRIAL COMPARING EPIRUBICIN MONOCHEMOTHERAPY TO 2 FLUOROURACIL, CYCLOPHOSPHAMIDE, AND EPIRUBICIN REGIMENS DIFFERING IN EPIRUBICIN DOSE IN ADVANCED BREAST-CANCER PATIENTS
BONNETERRE, J
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (02) : 305 - 312
[39] FEC (FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE) VERSUS EM (EPIRUBICIN AND MITOMYCIN-C) WITH OR WITHOUT LONIDAMINE AS FIRST LINE TREATMENT FOR ADVANCE BREAST-CANCER - A MULTICENTRIC RANDOMIZED STUDY - PRELIMINARY-REPORT
PACINI, P
ALGERI, R
RINALDINI, M
GUARNIERI, A
BASTIANI, P
BARSANTI, G
NERI, B
MARZANO, S
TUCCI, E
INTERNATIONAL JOURNAL OF ONCOLOGY, 1994, 4 : 761 - 766
[40] Epirubicin/Docetaxel (ET) versus 5FU/Epirubicin/Cyclophosphamide (FEC) combinations as first line chemotherapy in patients with metastatic breast cancer [MBC].
Bonneterre, JM
Dieras, V
Tubiana-Hulin, M
Bougnoux, P
Bonneterre, MEA
Bendahmane, B
BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 215 - 215

← 1 2 3 4 5 →